Michael J. Overman
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (33)
Structural casual model of the relationship between the number of SEPs, confounding variables, and the percent of SEPs published. Orange represents the exposure of interest (number of SEPs), yellow represents the outcome of interest (percent of SEPs published), and the red arrow indicates the causal path. Green circles indicate confounders, blue circles indicate non-confounding ancestors of the exposure and outcome. Black arrows represent biasing pathway.
Year:
2025
Full multivariable model evaluating the association between the number of SEPs and the percentage of SEPs published among sensitivity analysis SEPs from both the protocol and ClinicalTrials.Gov, from trials with multiple protocols available.
Year:
2025
Comparison of publication and reporting between the overall dataset and the sensitivity analysis restricting SEPs to only those from both the protocol and ClinicalTrials.Gov, from trials with multiple protocols available.
Year:
2025
Purpose: Mismatch repair–deficient (dMMR) tumors have demonstrated favorable responses to immune checkpoint inhibition targeting PD-1. However, more in-depth identification of predictors of response could further refine patient selection for immunotherapy treatment. Patients and Methods: We undertook integrated evaluation performed on samples collected from 28 of 42 patients enrolled on the NCI–Molecular Analysis for Therapy Choice arm Z1D trial that evaluated PD-1 inhibition treatment with nivolumab in patients with noncolorectal dMMR tumors. Genomic analyses were performed using next-generation sequencing (NGS), whole-exome sequencing, and RNA sequencing and supplemented by multiplex immunofluorescence performed on tissue samples. Results: In this dMMR population, more extensive alterations of microsatellites as assessed by measures of NGS were associated with clinical benefit and tumor mutational burden. RNA sequencing further revealed associations between clinical benefit and immune infiltration index. Gene sets enriched in patients with clinical benefit included IFN signaling, antigen processing, and PI3K–AKT–mTOR signaling, whereas hedgehog signaling was found to be enriched in subjects lacking clinical benefit. Conclusions: These genomic data highlight the importance of immune infiltration and antigen presentation in dMMR tumors that respond to immune checkpoint blockade. In addition, they suggest that, even within a dMMR population, NGS-based measures of microsatellite instability could serve as biomarkers of immunotherapy response.
Year:
2025
Purpose: Appendiceal adenocarcinoma is a rare malignancy with distinct histopathologic subtypes and a natural history with metastasis primarily limited to the peritoneum. Little is known about the molecular pathogenesis of appendiceal adenocarcinoma relative to common tumors. Experimental Design: We analyzed molecular data for patients within the Guardant Health database with appendix cancer ( n = 718). We then identified patients with appendiceal adenocarcinoma at our institution (from October 2004–September 2022) for whom ctDNA mutation profiling (liquid biopsy) was performed ( n = 168) and extracted clinicopathologic and outcomes data. Of these 168 patients, 57 also had tissue-based tumor mutational profiling, allowing for evaluation of concordance between liquid and tissue assays. Results: The mutational landscape of ctDNA in appendiceal adenocarcinoma is distinct from tissue-based sequencing, with TP53 being the most frequently mutated (46%). Relative to other tumors, appendiceal adenocarcinoma seems less likely to shed ctDNA, with only 38% of patients with metastatic appendiceal adenocarcinoma having detectable ctDNA (OR = 0.26; P P ≤ 0.001). High-grade, signet ring, or colonic-type histology, metastatic spread beyond the peritoneum, and TP53 mutation were associated with detectable ctDNA. With respect to clinical translation, patients with detectable ctDNA had worse overall survival (HR = 2.32; P = 0.048). In the Guardant Health cohort, actionable mutations were found in 93 patients (13.0%). Conclusions: Although metastatic appendiceal adenocarcinoma tumors are less likely to shed tumor DNA into the blood relative to colorectal cancer, ctDNA profiling in appendiceal adenocarcinoma has clinical utility.
Year:
2025
Background Immune checkpoint inhibitors (ICIs) are recommended to treat patients with deficient mismatch repair/microsatellite instability high (dMMR/MSI-H) metastatic colorectal cancer (mCRC). Pivotal trials have fixed a maximum ICI duration of 2 years, without a compelling rationale. A shorter treatment duration has the potential to improve patients' quality of life and reduce both toxicity and cost without compromising efficacy. Here we examine whether early treatment discontinuation (ETD) before 13 months in patients without progressive disease (PD) can lead to similar long-term disease control compared with a longer treatment duration (LTD). Methods To assess whether ETD is associated with similar outcomes compared with LTD, we assembled an international cohort of patients with dMMR/MSI-H mCRC treated with ICIs who stopped treatment for a reason other than PD within 395 days (ETD group) and compared them to those who continued for >395 days (LTD group). Outcomes were adjusted for patient/tumor characteristics. Primary endpoint was progression-free survival (PFS) and secondary endpoints were objective response rate (ORR), overall survival (OS) and safety. Results Of 976 patients, 137 and 394 were allocated to the ETD and LTD groups, respectively. In the ETD group, treatment was discontinued due to toxicity (n=56), objective response (n=43), surgery (n=28), patient decision (n=2) or other reasons (n=8). Baseline characteristics were well balanced between the two groups: 22% in both groups received both anti-programmed death-(ligand) 1 (anti-PD-(L)1) + anti-cytotoxic T-lymphocyte antigen-4 (anti-CTLA-4); all others received anti-PD-(L)1 monotherapy. ORR to ICIs was 81% in both groups. Median duration of treatment was ~7 months in the ETD and ~24 months in the LTD group. After a median follow-up of 44 months (IQR: 30–67), similar PFS (HR: 0.92, 95% CI: 0.60 to 1.40, p=0.69) and OS (HR: 1.15, 95% CI: 0.66 to 1.99, p=0.62) from the start of ICIs were observed in ETD and LTD patients. In the ETD group, 28 (20%) patients had a PFS event and 9 restarted ICIs with a disease control rate of 66%. Conclusions In our international series of dMMR/MSI-H mCRC, ETD of ICIs in the absence of PD did not seem detrimental in terms of PFS and OS compared with continuing treatment beyond 1 year. Randomized clinical trials to compare short and long treatment duration are now warranted.
Year:
2025
Purpose: Mismatch repair–deficient (dMMR) tumors have demonstrated favorable responses to immune checkpoint inhibition targeting PD-1. However, more in-depth identification of predictors of response could further refine patient selection for immunotherapy treatment. Patients and Methods: We undertook integrated evaluation performed on samples collected from 28 of 42 patients enrolled on the NCI–Molecular Analysis for Therapy Choice arm Z1D trial that evaluated PD-1 inhibition treatment with nivolumab in patients with noncolorectal dMMR tumors. Genomic analyses were performed using next-generation sequencing (NGS), whole-exome sequencing, and RNA sequencing and supplemented by multiplex immunofluorescence performed on tissue samples. Results: In this dMMR population, more extensive alterations of microsatellites as assessed by measures of NGS were associated with clinical benefit and tumor mutational burden. RNA sequencing further revealed associations between clinical benefit and immune infiltration index. Gene sets enriched in patients with clinical benefit included IFN signaling, antigen processing, and PI3K–AKT–mTOR signaling, whereas hedgehog signaling was found to be enriched in subjects lacking clinical benefit. Conclusions: These genomic data highlight the importance of immune infiltration and antigen presentation in dMMR tumors that respond to immune checkpoint blockade. In addition, they suggest that, even within a dMMR population, NGS-based measures of microsatellite instability could serve as biomarkers of immunotherapy response.
Year:
2024
PURPOSE PD-1 inhibition is effective in patients with mismatch repair deficient (dMMR) solid tumors in a tumor-agnostic fashion. However, dMMR testing by immunohistochemistry (IHC) is not routinely performed across tumor types. By contrast, next-generation sequencing (NGS) for somatic genomic alterations is frequently performed across tumor types. We hypothesized that NGS would identify patients with alterations in mismatch repair (MMR) genes and that these patients would have higher rates of MMR protein loss by IHC. This would support the utility of IHC reflex testing after NGS and potential matching to approved therapeutic options. METHODS From January 2016 to December 2021, 15,701 patients with solid tumors received NGS covering the MMR genes, and 4,994 patients had both IHC and NGS. Sequencing results were analyzed for mutations in MMR genes, tumor type distribution, and concordance with IHC results when available. RESULTS Six hundred and ninety-eight (4.4%) of 15,701 patients had mutations in one of the MMR genes. Mutations were found across tumor types. Three hundred and seventeen (6.3%) of 4,994 patients displayed IHC loss for at least one MMR protein. 33.8% patients (110/325) patients with MMR mutations had dMMR, compared with just 4.4% (207/4,669) patients without mutations ( P < .001); dMMR rate varied by mutation type. CONCLUSION Mutations in MMR genes are found in multiple tumor types where IHC testing is not routine. Reflex IHC testing of patients carrying MMR gene mutations, especially those known or inferred to be inactivating, may identify more patients with dMMR and matched treatment options. However, dedicated IHC screening is needed to capture majority of the patients.
Year:
2024
A, PFS and ( B ) OS in the dose-expansion phase overall (ITT) population; ( C ) PFS and ( D ) OS in patients with low CD73 levels, and ( E ) PFS and ( F ) OS in patients with high CD73 levels. ITT, intent-to-treat; NC, not calculable.
Year:
2024
CONSORT diagram for the dose-expansion phase. “a” denotes arm A1: death ( n = 1); withdrawal by patient ( n = 8); other ( n = 4). Arm A3: death ( n = 1); withdrawal by patient ( n = 2); other ( n = 2). “b” denotes patients could be counted more than once in this category if they discontinued different chemotherapy options for different reasons. “c” denotes as permitted per study protocol, patients from arms A2 and A3 continued to receive immunotherapy off-study after the study closure on July 22, 2022, and patients from all arms continued to receive treatment per standard of care at their site. “d” denotes end of study status as defined in the protocol. “e” denotes “sponsor decision" and includes patients either still on treatment or in survival follow-up at the time of study closure. N , number of patients in each treatment group.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (40)
Pavlos Msaouel
The University of Texas MD Anderson Cancer Center
Scott E. Kopetz
The University of Texas MD Anderson Cancer Center
Matthew Reilley
Assistant Professor
University of Virginia School of Medicine
Richard Yang
Assistant Professor, Molecular Genetic Pathology
The University of Texas MD Anderson Cancer Center
Kanwal Raghav
Professor
The University of Texas MD Anderson Cancer Center
Mariano Ponz-Sarvise
Universidad de Navarra
Wells Messersmith
Professor and Cancer Center Director
University of Colorado Cancer Center
John Paul Shen
The University of Texas MD Anderson Cancer Center
Daniel M Halperin
Vice Chair for Clinical Affairs
Winship Cancer Institute of Emory University
Abhineet Uppal
Assistant Professor
Emory University
Chantale Bernatchez
The University of Texas MD Anderson Cancer Center
Joseph Abi Jaoude
Stanford Health Care
Melissa Taggart
Associate professor
The University of Texas MD Anderson Cancer Center
Niharika Mettu
Duke University
Filippo Pietrantonio
Researcher (non-academic)
Fondazione IRCCS Istituto Nazionale dei Tumori
Andrew Futreal
Chair and Professor
The University of Texas MD Anderson Cancer Center
Fumiko Chino
The University of Texas MD Anderson Cancer Center
Christine Parseghian
Assistant Professor
The University of Texas MD Anderson Cancer Center
Anne Noonan
Professor
The Ohio State University Comprehensive Cancer Center
david tougeron
-
Ramez Kouzy
The University of Texas MD Anderson Cancer Center
Beth Helmink
Assistant Professor
The University of Texas MD Anderson Cancer Center
Ethan Ludmir
The University of Texas MD Anderson Cancer Center
Scott Rodig
Professor of Pathology
Beth Israel Deaconess Medical Center
Michael White
Assistant Professor
-
Ryan Sun
Assistant Professor
The University of Texas MD Anderson Cancer Center
Cara Haymaker
Associate Professor
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam
The University of Texas MD Anderson Cancer Center
Teresa Macarulla
Head of Gastrointestinal and Endocrine Tumor Unit
Hospital Clínic de Barcelona
julien taieb
Professor Head of the department
Université Paris-Saclay
Sara Lonardi
Head of Dept
Istituto Oncologico Veneto
Adina Passy
University of North Texas Health Science Center
Andrew Coveler
Fred Hutchinson Cancer Research Center
Neal Bhutiani
Assistant Professor
University of Louisville
Nataliya Uboha
Associate Professor
University of Wisconsin-Madison Carbone Cancer Center
Timothy Newhook
Assistant Professor
The University of Texas MD Anderson Cancer Center
Nick Pavlakis
Professor
University of Sydney
keith fournier
Associate Professor of Surgery
The University of Texas MD Anderson Cancer Center
Suyu Liu
Associate Professor
The University of Texas MD Anderson Cancer Center
Christos Fountzilas
Associate Professor
Roswell Park Comprehensive Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.